KR20230092932A - 항 pd-1/cd40 이중특이성 항체 및 그 용도 - Google Patents

항 pd-1/cd40 이중특이성 항체 및 그 용도 Download PDF

Info

Publication number
KR20230092932A
KR20230092932A KR1020237014700A KR20237014700A KR20230092932A KR 20230092932 A KR20230092932 A KR 20230092932A KR 1020237014700 A KR1020237014700 A KR 1020237014700A KR 20237014700 A KR20237014700 A KR 20237014700A KR 20230092932 A KR20230092932 A KR 20230092932A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
cdr1
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014700A
Other languages
English (en)
Korean (ko)
Inventor
바이홍 리우
이 양
유에레이 쉔
Original Assignee
유큐(베이징) 바이오파마 코., 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유큐(베이징) 바이오파마 코., 엘티디 filed Critical 유큐(베이징) 바이오파마 코., 엘티디
Publication of KR20230092932A publication Critical patent/KR20230092932A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020237014700A 2020-10-14 2021-10-13 항 pd-1/cd40 이중특이성 항체 및 그 용도 Pending KR20230092932A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/120918 2020-10-14
CN2020120918 2020-10-14
CN2021085335 2021-04-02
CNPCT/CN2021/085335 2021-04-02
PCT/CN2021/123438 WO2022078357A1 (en) 2020-10-14 2021-10-13 Anti-pd-1/cd40 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20230092932A true KR20230092932A (ko) 2023-06-26

Family

ID=81207517

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014700A Pending KR20230092932A (ko) 2020-10-14 2021-10-13 항 pd-1/cd40 이중특이성 항체 및 그 용도

Country Status (11)

Country Link
US (1) US20230220082A1 (https=)
EP (1) EP4229096A4 (https=)
JP (1) JP2023545521A (https=)
KR (1) KR20230092932A (https=)
CN (1) CN116390755A (https=)
AU (1) AU2021359495A1 (https=)
BR (1) BR112023006989A2 (https=)
CA (1) CA3197463A1 (https=)
IL (1) IL302042A (https=)
MX (1) MX2023004275A (https=)
WO (1) WO2022078357A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624372A (zh) * 2022-08-26 2024-03-01 北京天广实生物技术股份有限公司 靶向cd40和pd-l1的抗体及其用途
CN116023495B (zh) * 2022-09-05 2023-10-03 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
KR20250071228A (ko) * 2022-09-20 2025-05-21 커러스 바이오로직스 피티와이 엘티디 고갈된 면역 세포를 구제하는 방법
CN120584137A (zh) * 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110114089A (zh) * 2016-11-02 2019-08-09 埃派斯进有限公司 组合中的抗cd40抗体及其使用方法
EP3755716A4 (en) * 2018-02-23 2021-08-04 Eucure (Beijing) Biopharma Co., Ltd ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3823987A4 (en) * 2018-07-20 2022-03-02 Eucure (Beijing) Biopharma Co., Ltd ANTI-CD40 ANTIBODIES AND USES THEREOF
JP7575100B2 (ja) * 2018-11-13 2024-10-29 ジェイエヌ バイオサイエンシーズ エルエルシー 免疫細胞活性化のための二重特異性抗体
KR20220103957A (ko) * 2019-10-23 2022-07-25 리브젠 바이오파마 홀딩스 리미티드 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체

Also Published As

Publication number Publication date
IL302042A (en) 2023-06-01
AU2021359495A1 (en) 2023-04-13
JP2023545521A (ja) 2023-10-30
EP4229096A1 (en) 2023-08-23
CN116390755A (zh) 2023-07-04
US20230220082A1 (en) 2023-07-13
CA3197463A1 (en) 2022-04-21
BR112023006989A2 (pt) 2024-01-02
MX2023004275A (es) 2023-05-02
EP4229096A4 (en) 2024-06-12
WO2022078357A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
JP7685771B2 (ja) 二重特異性抗体およびその使用
KR102608723B1 (ko) 항―ｐｄ－１ 항체 및 그의 용도
KR20230092932A (ko) 항 pd-1/cd40 이중특이성 항체 및 그 용도
US20240002539A1 (en) Multispecific antibodies and uses thereof
US20240109963A1 (en) Multispecific antibodies and uses thereof
KR20220089688A (ko) 항-pd-1 항체 및 이의 용도
KR20200088810A (ko) 항―ｏｘ４０ 항체 및 그의 용도
CN113660956B (zh) 双特异性抗体及其用途
WO2021098851A1 (en) Anti-ctla4/ox40 bispecific antibodies and uses thereof
WO2023143597A1 (en) Anti-ctla4/ox40 bispecific antibodies and uses thereof
JP2025503229A (ja) 抗ｈｅｒ２／ｔｒｏｐ２抗体及びその使用
RU2859563C2 (ru) Биспецифические антитела к pd-1/cd40 и их применение
US20250129174A1 (en) Anti-4-1-1bbxccr8 antibodies and uses thereof
US20250270318A1 (en) Multispecific antibodies and uses thereof
HK40089128A (zh) 抗pd-1/cd40双特异性抗体及其用途
RU2783314C2 (ru) Антитела против ox40 и их применения
CN119110807A (zh) 抗cd40抗体及其用途
HK40117288A (zh) 抗cd40抗体及其用途
CN119947749A (zh) 多特异性抗体及其用途
CN119708244A (zh) 抗4-1bb×ccr8抗体及其用途
CN120380021A (zh) 抗pdl1抗体及其用途
HK40064279A (en) Bispecific antibodies and uses thereof
HK40115176A (zh) 双特异性抗体及其用途
HK40064279B (zh) 双特异性抗体及其用途
HK40033364A (en) Bispecific antibodies and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230428

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241010

Comment text: Request for Examination of Application